Memantina Kern Pharma (Memantine Hydrochloride)

Memantina Kern Pharma (memantine) is indicated for the management of Alzheimer’s disease, targeting the glutamatergic pathway that contributes to neurodegeneration.

• Alzheimer’s disease (moderate to severe): improves cognition and daily functional abilities.
• Alzheimer’s disease (mild to moderate): may slow the progression of memory loss and executive dysfunction.
• Alzheimer’s disease (behavioral symptoms): may reduce agitation, aggression and psychosis associated with the disease.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor‑associated ion channel. By binding within the channel at moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission. The drug’s voltage‑dependent blocking properties allow it to preferentially inhibit pathological over‑activation without disrupting physiological neurotransmission.

Memantina Kern Pharma may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness.
• Nausea: occasional upset stomach.
• Vomiting: occasional emesis.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Hallucinations: visual or auditory disturbances.
• Severe confusion: marked disorientation or delirium.
• Psychosis: emergence of delusional thoughts.

When prescribing Memantina Kern Pharma, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust dose or monitor renal function in patients with reduced clearance.
• Hepatic dysfunction: use with caution in moderate to severe liver disease.
• Concomitant NMDA antagonists: avoid combined use due to additive CNS effects.
• History of seizures: monitor closely as memantine may lower seizure threshold.
• Cardiovascular disease: assess risk as dizziness may affect blood pressure.
• Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Memantine can interact with other medicines, influencing its plasma levels or enhancing central nervous system effects.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse events.
• Ketamine: additive NMDA blockade can lead to excessive sedation or psychotomimetic effects.
• High‑dose quinidine: may raise memantine concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may worsen cognitive impairment when used together.
• Carbamazepine: enzyme induction may reduce memantine exposure.
• Proton pump inhibitors: may slightly increase memantine levels, requiring observation.